Logo

ITGR

Integer Holdings Corporation

ITGR

Integer Holdings Corporation • NYSE
$72.18 ▲ 0.19% (+0.14)
Market Cap $2.53 B
52w High $146.36
52w Low $62.00
Dividend Yield 0%
P/E 29.7
Volume 170.62K
Outstanding Shares 35.04M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $467.691M ▼ $69.721M ▼ $39.678M ▲ 8.484% ▲ $1.13 ▲ $88.399M ▼
Q2-2025 $476.494M ▲ $71.253M ▲ $37.009M ▲ 7.767% ▲ $1.06 ▲ $96.213M ▲
Q1-2025 $437.392M ▼ $71.167M ▲ $-22.487M ▼ -5.141% ▼ $-0.66 ▼ $85.227M ▼
Q4-2024 $449.497M ▲ $59.764M ▲ $32.703M ▼ 7.275% ▼ $0.97 ▼ $86.457M ▼
Q3-2024 $431.417M $59.426M $35.439M 8.215% $1.05 $89.638M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $58.944M ▲ $3.397B ▲ $1.651B ▼ $1.746B ▲
Q2-2025 $23.135M ▼ $3.371B ▲ $1.667B ▼ $1.704B ▲
Q1-2025 $31.711M ▼ $3.298B ▲ $1.691B ▲ $1.607B ▼
Q4-2024 $46.543M ▲ $3.078B ▼ $1.459B ▼ $1.619B ▼
Q3-2024 $35.574M $3.168B $1.546B $1.621B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $39.678M ▲ $65.595M ▲ $-20.268M ▼ $-10.711M ▲ $35.809M ▲ $46.259M ▼
Q2-2025 $37.009M ▲ $43.862M ▲ $-17.827M ▲ $-35.589M ▼ $-8.576M ▲ $69.08M ▲
Q1-2025 $-22.487M ▼ $31.276M ▼ $-197.167M ▼ $151.578M ▲ $-14.832M ▼ $6.058M ▼
Q4-2024 $32.703M ▼ $63.231M ▼ $29.617M ▲ $-82.304M ▼ $10.969M ▲ $44.141M ▼
Q3-2024 $35.439M $71.5M $-26.235M $-43.143M $1.437M $45.235M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Cardiac Rhythm Management Neuromodulation
Cardiac Rhythm Management Neuromodulation
 $500.00M ▲$160.00M ▼$170.00M ▲$170.00M ▲
Cardio And Vascular
Cardio And Vascular
 $710.00M ▲$260.00M ▼$290.00M ▲$280.00M ▼
Other Markets
Other Markets
 $0 ▲$20.00M ▲$20.00M ▲$20.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue and profits have been climbing at a steady pace over the past five years. Sales have grown each year, and profit margins have generally improved as the company scales. Operating profit and cash-style earnings have both moved higher, which suggests better efficiency and solid demand. Net income has been a bit up and down year to year, but the overall trend is upward, with earnings per share now well above where they were earlier in the period. This points to a business that is growing and becoming more profitable, not just bigger.

Balance Sheet

Balance Sheet The balance sheet has expanded over time, with both total assets and shareholders’ equity rising. Debt has also increased, but at a controlled pace, and equity growth has kept up, which helps support financial stability. One watch point is that the company tends to run with a relatively small cash balance, which leaves less of a cushion and makes access to credit and consistent cash generation important. Overall, the capital structure looks balanced but does rely on ongoing healthy operations.

Cash Flow

Cash Flow Cash generated from day‑to‑day operations has improved over the period, showing that earnings are being converted into cash reasonably well. Free cash flow is positive, but it has been somewhat uneven because the company is spending more on capital investment. Those higher investments likely support growth, capacity, and technology upgrades, but they do temporarily limit the excess cash available after spending. The pattern suggests a company in an investment phase, funding expansion from its own cash flows while keeping things generally positive.

Competitive Edge

Competitive Edge Integer operates as a key manufacturing and technology partner to large medical device companies, especially in complex areas like cardiac rhythm management, neuromodulation, and cardiovascular devices. Its strength lies in deep, long-term customer relationships, broad capabilities that span from design to finished devices, and a global manufacturing footprint. High regulatory hurdles and the complexity of switching suppliers give it meaningful staying power with customers. Vendor consolidation trends in the industry also favor players like Integer that can act as a one‑stop shop. The main risks are dependence on a relatively concentrated customer base and exposure to healthcare product cycles and regulatory changes.

Innovation and R&D

Innovation and R&D The company’s innovation engine is rooted in decades of experience in critical implantable technologies, particularly batteries and components for pacemakers and neuromodulation devices. Integer continues to push into smaller, longer‑lasting power solutions and advanced delivery systems for heart and neurovascular procedures. It has added specialized capabilities through acquisitions in micro‑machining and advanced coatings, broadening its toolkit for customers. Looking forward, it is positioned in promising areas such as pulsed‑field ablation, next‑generation neuromodulation, miniaturized smart devices, and more automated, data‑driven manufacturing. The key question is execution: successfully integrating acquisitions and keeping pace with rapid technology shifts will be critical.

Summary

Integer shows the profile of a growing medical device manufacturing partner with improving profitability, a stronger asset base, and a clear strategic focus on complex, high‑value medical technologies. Financially, the company appears to be using rising cash flows to reinvest heavily in capacity and capability, which supports future growth but keeps free cash flow somewhat tight. Its competitive moat is built on long‑term customer integration, regulatory know‑how, and broad, vertically integrated services that are hard to replicate quickly. On the risk side, relatively low cash on hand, ongoing reliance on debt, customer concentration, acquisition integration, and regulatory and technology shifts in healthcare are all important to monitor. Overall, Integer looks like an established player leaning into higher‑growth niches within medical devices, with both meaningful strengths and execution risks to watch.

NEWS

November 18, 2025 · 8:00 AM UTC

Integer to Participate at Upcoming Investor Conferences

Read more

November 4, 2025 · 8:00 AM UTC

Integer Holdings Corporation Board Authorizes $200 Million Share Repurchase Program

Read more

October 24, 2025 · 8:00 AM UTC

Payman Khales Assumes Role as Integer President and CEO

Read more

October 23, 2025 · 8:00 AM UTC

Integer Holdings Corporation Reports Third Quarter 2025 Results

Read more

September 25, 2025 · 8:00 AM UTC

Integer Announces Conference Call to Discuss Third Quarter 2025 Results

Read more